Abstract
It is surprising that, while arsenic trioxide (ATO) is now considered as “the single most active agent in patients with acute promyelocytic leukemia (APL)”, the most important discoverer remains obscure and his original papers have not been cited by a single English paper. The discovery was made during the Cultural Revolution when most Chinese scientists and doctors struggled to survive. Beginning with recipes from a countryside practitioner that were vague in applicable diseases, Zhang TingDong and colleagues proposed in the 1970s that a single chemical in the recipe is most effective and that its target is APL. More than 20 years of work by Zhang and colleagues eliminated the confusions about whether and how ATO can be used effectively. Other researchers, first in China and then in the West, followed his lead. Retrospective analysis of data from his own group proved that APL was indeed the most sensitive target. Removal of a trace amount of mercury chloride from the recipe by another group in his hospital proved that only ATO was required. Publication of Western replication in 1998 made the therapy widely accepted, though neither Western, nor Chinese authors of English papers on ATO cited Zhang’s papers in the 1970s. This article focuses on the early papers of Zhang, but also suggests it worth further work to validate Chinese reports of ATO treatment of other cancers, and infers that some findings published in Chinese journals are of considerable value to patients and that doctors from other countries can benefit from the clinical experience of Chinese doctors with the largest population of patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ellison R R, Holland J F, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood, 1968, 32: 507–523
Boiron M, Weil M, Jacquillat C, et al. Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet, 1969, 293: 330–333
Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood, 1973, 41: 489–496
Bernard J, Weil M, Jacquillat C I. Treatment of acute granulocytic leukemias. Ann Rev Med, 1974, 25: 39–50
Zhang T D, Zhang P F, Wang S R, et al. Preliminary clinical observations of six cases of leukemia treated by “Ailin solution” (in Chinese) 1). Med Pharm Heilongjiang, 1973, (3): 66–67
Departments of Traditional Chinese Medicine and Laboratory Medicine of the First Affiliated Hospital of Harbin Medical University. Therapeutic observations of 17 cases leukemia treated with Ailin No.1 and dialectic theory (in Chinese). J Harbin Med Univ, 1974, (2): 25–30
Rong F X, Zhang T D. A report on long term survival of two cases of acute granulocytic leukemia (in Chinese). J New Med Pharm, 1979, (6): 31–34
Zhang T D, Rong F X. Treatment of acute granulocytic leukemia by Ailin No.1 and dialectic theory (in Chinese). Med Pharm Heilongjiang, 1979, (4): 7–11
Huang M E, Ye Y C, Chen S R, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia: report of six cases (in Chinese). Chin Med J, 1987, 100: 949–953
Huang M E, Ye Y C, Chen S R, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1988, 72: 567–572
Sanz M A, Grimwade D, Tallman M S, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2009, 113: 1875–1891
Tallman M S, Altman J K. How I treat acute promyelocytic leukemia. Blood, 2009, 114: 51260–51235
Sanz M A, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol, 2011, 29: 495–503
Powell B L, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010, 116: 3751–3757
Estey E H. Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center. J Clin Oncol, 2011, 29: 2743–2746
Sears D A. History of the treatment of chronic myelocytic leukemia. Am J Med Sci, 1988, 296: 85–86
Jolliffe D M. A history of the use of arsenicals in man. J Royal Soc Med, 1993, 86: 287–289
Guan J R. Leukemia: clinical analysis of 49 cases (in Chinese). Heilongjiang Med, 1958, (2): 22–34
Gu D X. Preliminary observations of the therapeutic effect of the traditional Chinese medicine “55” on leukemia (in Chinese). Harbin J Trad Chin Med, 1964, 5: 24
Chaoyang People’s Hospital Department of Pediatrics. Experience of using a combination of arsenic and chemotherapy to treat leukemia (in Chinese). Anti-Cancer Battle News of Liaoning (internally circulated materials, be careful in safekeeping, by the Office of Cancer Prevention and Treatment Research of Liaoning Province), 1972, (7): 23–24
Hematology Group of the Department of Internal Medicine at Xiyuan Hospital of the Chinese Academy of Traditional Medicine. Treatment of leukemia by traditional Chinese medicine (in Chinese). Guangdong Med, 1974, (5): 31–37
Zhou A X. Research on Qinghuang San treatment of leukemia (in Chinese). Chin J Integrat Trad West Med, 1998, 18: 582–583
Department of Traditional Chinese Medicine of the First Affiliated Hospital of Harbin Medical University (Supervisor: Zhang T D. Writers: Li Y S, Hu X C. Participants: Li M X, Zhang P F, Rong F X, et al.). A clinical summary of 73 cases treated by Ailin No.1 combined with the dialectic theory (in Chinese). Chin Med Pharm Heilongjiang, 1981, (4): 28–30
Zhang T D. Comments on questions about designing clinical research with combined Chinese and Western medicine (in Chinese). J Integrat Trad Chin West Med, 1982, 2: 180–181
Zhang T D. Understanding and treatment of leukemia by Chinese medicine (in Chinese). J Trad Chin Med, 1983, (3): 71–74
Zhang T D, Li Y S. Clinical findings and experimental research of Ailin No. 1 in treating acute granuloleukemia (in Chinese). J Integrat Trad Chin West Med, 1984, 4: 19–20
Zhang T D. Diagnosis and treatment of acute non-lymphatic leukemia (in Chinese). J Integrat Trad Chin West Med, 1985, 5: 713
Sun H D, Ma L, Hu X C, et al. A report on 16 acute promyelocytic leukemia cases of long term survival treated by Ailin No.1 in combination with traditional Chinese dialectic theories (in Chinese). Inf Trad Chin Med Pharm, 1991, (6): 39–41
Sun H D, Ma L, Hu X C, et al. Ailin I treated 32 cases of acute promyelocytic leukemia (in Chinese). Chin J Integrat Chin West Med, 1992, 12: 170–172
Zhang P, Wang S Y, Hu L H, et al. “713” (As2O3) treatment of 117 cases of acute promyelocytic leukemia: clinical observations and mechanistic investigations (in Chinese). J Harbin Med Univ, 1995, 29: 243
Zhang P, Wang S Y, Hu L H, et al. Treatment of 72 cases of acute promyelocytic leukemia with intravenous arsenic trioxide (in Chinese). Chin J Hematol, 1996, 17: 58–62
Collins S J, Gallo R C, Gallagher R E. Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. Nature, 1977, 270: 347–349
Breitman T R, Selonick S E, Collins S J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA, 1980, 70: 2936–2940
Breitman T R, Collins S J, Keene B R. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood, 1981, 57: 1000–1004
Olsson I L, Breitman T R. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3′: 5′-monophosphate-inducing agents. C Cancer Res, 1982, 42: 3924–3927
Honma Y, Fujita Y, Kasukabe T, et al. Induction of differentiation of human acute non-lymphocytic leukemia cells in primary culture by inducers of differentiation of human myeloid leukemia cell line HL-60. Eur J Cancer Clin Oncol, 1983, 19: 251–261
Koeffler H P. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood, 1983, 62: 709–721
Flynn P, Miller W, Weisdorf D, et al. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood, 1983, 62: 1211–1217
Nilsson B. Probable in vivo induction of differentiation by retinoic acid acid of promyelocytes in acute promyelocytic leukemia. British J Haematol, 1984, 57: 365–371
Daenen S, Vellenga E, van Dobbenbugh O A, et al. Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood, 1986, 67: 559–561
Fontana J A, Roger I S, Durham J P. The role of 13-cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer, 1986, 57: 209–217
Chomienne C, Ballerini P, Balitrand N, et al. Retinoic acid therapy for promyelocytic leukemia. Lancet, 1989, 334: 746–747
Castaigne S, Chomienne C, Daniel M T, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 1990, 76: 1704–1709
Chen Z X, Xue Y Q, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients. Blood, 1991, 78: 1413–1419
Warrell Jr R P, Frankel S T, Miller Jr W H, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med, 1991, 324: 1385–1393
Tallman M S, Andersen J W, Schiffer C A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med, 1997, 337: 1021–1028
Duan J X, Xin X M, Wang F Q, et al. Anti-cancer effect of Ailin No. 1 on leukemic cells of acute promyelocytic leukemia patients (in Chinese). Pract J Oncol, 1992, (2): 29–30
Huang S L, Guo A X, Xiang Y, et al. Clinical study on the treatment of APL mainly with composite Indigo Naturalis tablets (in Chinese). Chin J Hematol, 1995, 16: 26
Chen G Q, Zhu J, Shi X G, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood, 1996, 88: 1052–1061
Xu J S, Duan J M, Xu Y, et al. A case of APL survival of 20 years with treatment by Ailin I (in Chinese). Chin J Hematol, 1997, 18: 476
Chen G Q, Shi X G, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997, 89: 3345–3353
Shen Z X, Chen G Q, Ni J H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89: 3354–3360
Soignet S L, Maslak P, Wang Z G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 1998, 339: 1341–1348
Rosenthal E. Chairman Mao’s cure for cancer. New York Times, May 6th, 2001
Chen G Q, Chen S J, Wang Z Y, et al. (1998). Mechanisms and prospects of arsenic treatment of acute promyelocytic leukemia (in Chinese). Chin J Integrat Trad Chin West Med, 1998, 18: 581–582
Mervis J. Cancer research: ancient remedy performs new tricks. Science, 1996, 273: 578
Zhang T D, Chen G Q, Wang Z G, et al. Arsenic trioxide, a therapeutic agent for APL. Oncogene, 2001, 20: 7146–7153
Zhu J, Chen Z, Lallemand-Breitenbach V, et al. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer, 2001, 2: 705–714
Wang Z Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008, 111: 2505–2515
Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999, 94: 3315–3324
Chen S J, Zhou G B, Zhang X W, et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011, 117: 6425–6437
Zhang P. The history of discovering arsenic trioxide (in Chinese). http://blog.sciencenet.cn/blog-870683-663068.html, 2013
Au W Y, Kumana C R, Lee H K K, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood, 2011, 118: 6535–6543
Li Y S, Zhang T D, Wang X R, et al. Investigation of the dynamics of Ailin No. 1 on human liver cancer cells (in Chinese). Res Cancer Prevent Treat, 1988, 15: 1–3
Liu L X, Zhu A L, Chen W, et al. Effect of arsenic trioxide on hepatocellular carcinoma and its mechanistic studies. Chin J Surg, 2005, 43: 33–36
Guo H X, Chen W, Liu L X, et al. Recent status of the effect of arsenic trioxide on colon cancer. Chin J Integr Trad West Med Dig, 2006, 14: 207–209
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Rao, Y., Li, R. & Zhang, D. A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Sci. China Life Sci. 56, 495–502 (2013). https://doi.org/10.1007/s11427-013-4487-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-013-4487-z